Small-cell carcinoma

EQS-News: DEFENCE THERAPEUTICS INITIATES LUNG CANCER TREATMENT PROGRAM WITH ITS NOVEL ACCUTOXTM FORMULATION VIA INTRANASAL

Retrieved on: 
Wednesday, October 12, 2022
Therapy, Hand, DNA repair, Vaccine, CAGR, Neoplasm, DNA replication, Research, Malignancy, Cell, Technology, Cancer, Infection, Chemistry (relationship), Lung cancer, Company, Cell death, CSE, CEO, ADC, Small-cell carcinoma, News, Genome, Defense, Forward-looking statement, DNA, Cell division, Catastrophic illness, USD, Carcinoid syndrome, Engineering, Control, Large-cell lung carcinoma, Security (finance), BC

The novel AccuTOXTM formulation is designed for the treatment of lung cancer including various types of malignancy of the upper or lower respiratory tracks.

Key Points: 
  • The novel AccuTOXTM formulation is designed for the treatment of lung cancer including various types of malignancy of the upper or lower respiratory tracks.
  • The AccuTOXTM will be delivered intranasal to effectively deliver the AccuTOXTM into the transmucosal and will target the lungs.
  • The AccuTOXTM technology is an AccumTM variant developed by Defence Therapeutics to specifically halt tumor growth when administered intratumorally.
  • Small cell lung cancer, lung carcinoid tumor and non-small cell lung cancer are three different types of lung cancer.

LUNGevity Launches New Small Cell Lung Cancer Patient Gateway

Retrieved on: 
Tuesday, August 16, 2022
Jazz Pharmaceuticals, Smoker, Multimedia, Survival, Helpline, SCLC, Lung cancer, CEO, Small-cell carcinoma, Clinical trial, Merck Serono, Smoking, BUT, Caregiver, Research, Human, Charity Navigator, Health equity, Cancer, NSCLC, Patient, Quality of life, EGFR, ALK, KRAS, Survivor, Strathcona County, Squamous cell carcinoma, Treatment of lung cancer, News, Fellow, AstraZeneca, Conference, Public policy, Disease, Residential care, Medical imaging, Pharmaceutical industry, Genentech, Gateway

WASHINGTON, Aug. 16, 2022 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, has launched the Small Cell Lung Cancer Patient Gateway. This new resource completes the suite of six Patient Gateways, where lung cancer survivors can access relevant information tailored to their specific subtype. Small cell lung cancer accounts for 15% of all lung cancers and is often diagnosed in people with a history of smoking. The Gateway allows survivors to locate specialists and resources more easily. The Patient Gateway also features information on treatment options and the ability to connect with a community of fellow survivors and their caregivers.

Key Points: 
  • The specialized resource offers patients with small cell lung cancer (SCLC) and their caregivers access to treatment information, informative webinars, the latest scientific news, and a supportive community
    WASHINGTON, Aug. 16, 2022 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, has launched the Small Cell Lung Cancer Patient Gateway .
  • The Small Cell Lung Cancer Patient Gateway is a user-friendly and easily accessible information portal that offers the latest medical updates and practical resources for patients and their caregivers.
  • The Small Cell Lung Cancer Patient Gateway joins the EGFR, KRAS, ALK, Rare Mutations and Fusions, and Non-Small Cell Lung Cancer (NSCLC) platforms at gateway.lungevity.org .
  • The Small Cell Lung Cancer Patient Gateway is supported by generous sponsorships from AstraZeneca, EMD Serono, Genentech, and Jazz Pharmaceuticals.

Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Cancer, CEO, DLL3, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Toxicity, Food, U.S. Securities and Exchange Commission, Patient, Small-cell carcinoma, Dana–Farber Cancer Institute, Therapy, Pharmacokinetics, Society, American Society of Clinical Oncology, COVID-19, Lymphatic system, Cytokine release syndrome, FDA, SAN, Squamous cell carcinoma, Principal, Antigen, Prostate cancer, Forward-looking statement, Safety, CRS, ASCO, SCLC, Neoplasm, Protein, GLOBE, Pharmaceutical industry, Vaccine, Harpoon

The first scientific presentation of these interim data will be featured in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022, taking place in Chicago from June 3-7.

Key Points: 
  • The first scientific presentation of these interim data will be featured in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022, taking place in Chicago from June 3-7.
  • To date, there have been no dose-limiting toxicities observed and no discontinuations due to adverse events.
  • No grade 3 or higher CRS or any immune effector cell associated neurotoxicity syndrome (ICANS) events have been observed.
  • In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to HPN328 for the treatment of SCLC.

Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, March 28, 2022
Administration, Therapy, Pemetrexed, Aileron, Form 10-K, Private Securities Litigation Reform Act, Patent, Investment, Cyclophosphamide, MOA, Clinical trial, ALRN, Coronavirus, Annual report, Neutropenia, CMC, Patient, Cancer, Doxorubicin, U.S. Securities and Exchange Commission, NSCLC, Security (finance), Anemia, Thrombocytopenia, G&A, Safety, Small-cell carcinoma, Nasdaq, GLOBE, Docetaxel, NDA, Toxic leukoencephalopathy, R, Research and development, Breast cancer, SCLC, Toxicity, Birth control, Cryptocurrency, Pharmaceutical industry, Medical device, Medical imaging, Health insurance

Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2021 were $4.6 million, compared to $1.9 million for the fourth quarter of 2020.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2021 were $4.6 million, compared to $1.9 million for the fourth quarter of 2020.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2021 were $2.3 million, compared to $2.3 million for the fourth quarter of 2020.
  • Net Loss: Net loss for the fourth quarter of 2021 was $6.8 million, compared to $4.9 million for the fourth quarter of 2020.
  • The basic and diluted net loss per share for the fourth quarter of 2021 was $0.08 compared to $0.12 for the fourth quarter of 2020.

Global Lung Cancer Diagnostics Market (2021 to 2027) - Impact Analysis of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 29, 2021
Health, Biotechnology, Fatality, Magnetism, Lung cancer, Diagnosis, COVID-19, X-ray, Magnetic resonance imaging, Risk, Cancer, Squamous cell carcinoma, SCLC, Field line, Smoking, Nuclear, Hospital, Prevalence, Large-cell lung carcinoma, Cell, Research, Adenocarcinoma, Patient, Non-small-cell lung carcinoma, MRI, Clifton Springs Hospital & Clinic, Awareness, NSCLC, Industry, Small-cell carcinoma, Medical imaging, Uranium

The two chief types of lung cancer are small-cell lung cancer and non-small cell lung cancer, depending on their appearance under a microscope.

Key Points: 
  • The two chief types of lung cancer are small-cell lung cancer and non-small cell lung cancer, depending on their appearance under a microscope.
  • Non-small cell lung cancer (NSCLC) is the unique form of cancer and accounts for 85% of lung cancer cases.
  • As per our analysis, non-small cell lung cancer dominates small cell lung cancer around the world.
  • Consequently, helping to track treatment progress and capture the highest market share in the Lung Cancer Diagnostics Market.

Jazz Pharmaceuticals Announces Commercial Availability in Canada of Zepzelca™ (lurbinectedin), the First New Treatment for Stage III or Metastatic Small Cell Lung Cancer in More Than a Decade

Retrieved on: 
Tuesday, November 30, 2021
People, Commission, Cell, Risk, Company, Diagnosis, Amp, Hope, McMaster University, Lung cancer, RNA interference, CNS, Time, Government of Canada, Gene silencing, Cancer, MSE, SCLC, Research, Squamous cell carcinoma, Patient, PharmaMar, Failure, Statistics, News, Daily, Health Canada, Jazz Pharmaceuticals, Lung, Twitter, Adult, NASDAQ, Tobacco, Toxicity, Growth, Tissue, Small-cell carcinoma, COVID-19, Treatment of lung cancer, Juravinski Cancer Centre, Science, Disease, Pharmaceutical industry, Uranium, Health insurance

says Paul Petrelli,general manager, Jazz Pharmaceuticals Canada Inc."We areproudto introduce this meaningful new treatment to patients in Canada."

Key Points: 
  • says Paul Petrelli,general manager, Jazz Pharmaceuticals Canada Inc."We areproudto introduce this meaningful new treatment to patients in Canada."
  • "Patients with small cell lung cancer in the second line and their families have been on the sidelines for far too long.
  • The availability of Zepzelca in Canada is a great new option," says Shem Singh, executive director,Lung Cancer Canada.
  • Small cell lung cancer is sometimes, but not often, called oat cell cancer because the small, oval-shaped cells look like oat grains under a microscope.

Drs. Erik Knelson, Dwight Owen, and Erin Schenk receive 10th annual LUNGevity Career Development Awards

Retrieved on: 
Thursday, September 16, 2021
United States Air Force Scientific Advisory Board, Myeloid-derived suppressor cell, Education, Patient, Strathcona County, Neoplasm, Policy, Breast, Large-cell lung carcinoma, Smoker, Thomas, Lung cancer, MPH, Research, Prostate, MDSC, Program, Science, Caregiver, TME, Helpline, Survival, NSCLC, Cancer, Squamous cell carcinoma, Immunotherapy, Cell, Bristol Myers Squibb, Ohio, Immunity, CDA, BUT, Tumor microenvironment, Small-cell carcinoma, Recurrence, Memorial Sloan Kettering Cancer Center, Health equity, Survivor, Public policy, Quality of life, University, Doctor of Philosophy, Treatment of lung cancer, TKI, Multimedia, Human, Oncogene, Pharmaceutical industry, Vaccine, Medical imaging

LUNGevity is proud to support the following 2021 Career Development Award projects:

Key Points: 
  • LUNGevity is proud to support the following 2021 Career Development Award projects:
    Erik Knelson, MD, PhD, Dana-Farber Cancer Institute Co-opting small-cell lung cancer plasticity to enhance antitumor immunity.
  • Dwight Owen, MD, The Ohio State University Comprehensive Cancer Center Targeting myeloid-derived suppressor cells in lung cancer.
  • MDSCs represent an important tumor immune escape mechanism and play a role in the development and progression of lung cancer.
  • LUNGevity is the only lung cancer organization with a programmatic focus on early detection and a robust Career Development Award Program.

LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY

Retrieved on: 
Tuesday, August 3, 2021
Cancer, Lung cancer, Infectious causes of cancer, Neoplasms, Health, Treatment of cancer, Small-cell carcinoma

Pasadena, CA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXT) announced that its lead clinical compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to enhance the effectiveness of elements of standard therapy in models of small cell lung cancer (SCLC) (Mirzapoiazova el al., Molecular Cancer Therapeutics, online July 12, 2021).

Key Points: 
  • A Pre-Clinical Study Reports that LB-100 Potentiates Standard Therapy for Small Cell Lung Cancer Providing a Strong Rationale for a Clinical Trial of LB-100 in Small Cell Lung Cancer Recently Initiated at City of Hope.
  • A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off.
  • The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning.
  • This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml .

Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit

Retrieved on: 
Wednesday, July 14, 2021
Clinical medicine, Cancer treatments, Medicine, Cancer immunotherapy, Lung cancer, Antineoplastic drugs, Breakthrough therapy, Orphan drugs, Advaxis, Pembrolizumab, Merck & Co., Small-cell carcinoma

PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez, M.D., Executive Vice President and Chief Medical Officer of Advaxis, will present data from Part B of the Companys Phase 1/2 study of ADXS-503 in combination with Pembrolizumab in patients with metastatic squamous or non-squamous non-small cell lung cancer at the virtual Non-Small Cell Lung Cancer Drug Development Summit on July 15th, 2021.

Key Points: 
  • PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez, M.D., Executive Vice President and Chief Medical Officer of Advaxis, will present data from Part B of the Companys Phase 1/2 study of ADXS-503 in combination with Pembrolizumab in patients with metastatic squamous or non-squamous non-small cell lung cancer at the virtual Non-Small Cell Lung Cancer Drug Development Summit on July 15th, 2021.
  • Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products.
  • These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,Kenilworth, N.J., USA.

Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Health, Oncology, Cancer, Lung cancer, Infectious causes of cancer, Health, Neoplasms, Carcinoma, Cytopathology, Small-cell carcinoma, G1 Therapeutics

This "Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape.

Key Points: 
  • This "Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape.
  • "Extensive-Stage Small Cell Lung Cancer (ESCLC)- Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape is provided which includes the disease overview and Extensive-Stage Small Cell Lung Cancer (ESCLC) treatment guidelines.
  • Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.